LENVIMA: Efficacy that drives results¹

Offering more time without disease progression¹

• 18.3 month (95% CI: 15.1-NE) median PFS was observed with LENVIMA vs 3.6 months (95% CI: 2.2-3.7) with placebo (HR: 0.21 [95% CI: 0.16-0.28]; P<0.001; primary endpoint)¹

  • Number of events: 107 (41%) with LENVIMA vs 113 (86%) with placebo

CI=confidence interval; NE=not estimable; PFS=progression-free survival; HR=hazard ratio; AR=adverse reaction.